Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2019 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Oral-visceral iatrogenic Kaposi sarcoma following treatment for acute lymphoblastic leukemia: a case report and review of the literature.
Nyeko R, Geriga F, Angom R, Kambugu JB. Nyeko R, et al. J Med Case Rep. 2022 Nov 4;16(1):405. doi: 10.1186/s13256-022-03620-3. J Med Case Rep. 2022. PMID: 36329498 Free PMC article. Review.
He was successfully treated for Kaposi sarcoma on a two-drug regimen (bleomycin and vincristine) with good clinical response. CONCLUSION: Visceral Kaposi sarcoma as a second malignancy may occur after pediatric acute lymphoblastic leukemia treatment, but its rarity makes i …
He was successfully treated for Kaposi sarcoma on a two-drug regimen (bleomycin and vincristine) with good clinical response. CONCLUS …
Iatrogenic Kaposi sarcoma of the small bowel in Crohn's disease following short-term use of immunomodulators: a case report and review of the literature.
Wu PJ, Sun CS, Kuo HT, Sheu MJ, Lin CY, Wang SH, Yang CC, Chen CH, Chuang SS, Feng IC. Wu PJ, et al. J Med Case Rep. 2022 Nov 7;16(1):424. doi: 10.1186/s13256-022-03637-8. J Med Case Rep. 2022. PMID: 36336687 Free PMC article. Review.
Kaposi sarcoma can occur in immunocompromised patients receiving immunosuppressive therapy, in which case it is known as iatrogenic Kaposi sarcoma or drug-induced Kaposi sarcoma. Intestinal Kaposi sarcoma in patients with inflammatory bowel disease is extreme …
Kaposi sarcoma can occur in immunocompromised patients receiving immunosuppressive therapy, in which case it is known as iatrogenic …
Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center.
Khanmammadov NA, Paksoy N, Doğan İ, Ferhatoğlu F, Saip P, Aydiner A. Khanmammadov NA, et al. Medicine (Baltimore). 2023 Sep 29;102(39):e35383. doi: 10.1097/MD.0000000000035383. Medicine (Baltimore). 2023. PMID: 37773844 Free PMC article.
Kaposi sarcoma is a malignant angioproliferative disease, and human herpesvirus-8 plays a major role in its etiology. Iatrogenic Kaposi sarcoma (IKS) can occur in patients undergoing immunosuppressive therapy. ...Therefore, we investigated the efficacy and sa …
Kaposi sarcoma is a malignant angioproliferative disease, and human herpesvirus-8 plays a major role in its etiology. Iatrogenic K …
Cutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases.
Binois R, Nadal M, Esteve E, De Muret A, Kerdraon R, Gheit T, Tommasino M, Gaboriaud P, Touze A, Samimi M. Binois R, et al. Eur J Dermatol. 2017 Aug 1;27(4):369-374. doi: 10.1684/ejd.2017.3027. Eur J Dermatol. 2017. PMID: 28659250
Iatrogenic Kaposi sarcoma (KS) has previously been reported in patients with bullous pemphigoid (BP), in relation to systemic steroids. ...In such cases, serum antibodies against HHV8 infection may be investigated in BP patients before introduction of MTX in …
Iatrogenic Kaposi sarcoma (KS) has previously been reported in patients with bullous pemphigoid (BP), in relation to sy …
Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.
Ingegnoli F, Tourlaki A, Gualtierotti R. Ingegnoli F, et al. Clin Drug Investig. 2014 Feb;34(2):159-61. doi: 10.1007/s40261-013-0159-9. Clin Drug Investig. 2014. PMID: 24307431
Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monocl …
Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new targ …